MarketBeat
22 Sept 2026, 00:02 UTC · 1d ago
Verdict
Headline takes no side. We score TEM +0.90 across five claims — strongly bullish.
+0.90strongly bullish
More positive than 94% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish · 0 new · 5 priced in
FDA approval for the liquid-biopsy assay could raise pricing from $3,200 to the mid- to high-$7,000 range, potentially creating $250 million to $300 million in annual uplift.
Priced incomments at Morgan Stanley conference
So whatThis represents a potential price increase of over 100% per test starting in H2 2027.
More positive than 99% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
The transition to ADLT pricing for core oncology assays is expected to provide $80 million to $100 million of incremental annual benefit beginning next year.
Priced incomments at Morgan Stanley conference
So whatThis creates a tangible floor for FY2026 margin expansion if these funds are not reinvested.
More positive than 92% of claims this week
Tempus won the RFP to support the potential national rollout of Merck and Moderna’s V940 personalized melanoma vaccine if it receives FDA approval.
Priced incomments at Morgan Stanley conference
More positive than 86% of claims this week
The data-licensing business grew approximately 36% in the most recent quarter with roughly $200 million in total contract value additions.
Priced inanalysis of Q2 performance
So whatThe 30% long-term oncology growth target suggests a slight deceleration from the recent 36% quarterly clip.
More positive than 77% of claims this week
Tempus expects its hereditary testing business to return to mid-teens growth toward the end of the year.
Priced incomments at Morgan Stanley conference
So whatRecovery begins in Q4 2026 after lapping the Invitae bankruptcy volume spikes.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
Strong Q2 performance, significant growth in data-licensing, and expected pricing uplifts from FDA approvals.
More positive than 57% of ticker scores this week
Mentioned as a partner in a potential national rollout of a personalized melanoma vaccine program.
More positive than 47% of ticker scores this week
Mentioned as a customer signing a long-term data agreement exceeding $100 million.
More positive than 47% of ticker scores this week
Mentioned as a customer signing a long-term data agreement exceeding $100 million.
More positive than 47% of ticker scores this week
Mentioned as a customer signing a long-term data agreement exceeding $100 million.
More positive than 47% of ticker scores this week
Mentioned as a customer signing a long-term data agreement exceeding $100 million.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
More positive than 17% of relationship scores this week
[a_to_b] Tempus AI has signed long-term oncology data licensing agreements with AstraZeneca.
More positive than 17% of relationship scores this week
[a_to_b] Tempus AI has signed long-term oncology data licensing agreements with Bristol Myers Squibb.
More positive than 17% of relationship scores this week
[a_to_b] Tempus AI has signed long-term oncology data licensing agreements with GSK.
More positive than 17% of relationship scores this week
[a_to_b] Tempus AI has signed long-term oncology data licensing agreements with Merck.
More positive than 17% of relationship scores this week
[a_to_b] Tempus AI has signed long-term oncology data licensing agreements with BioNTech.
−1.1%
Price is moving against the score
$77.19 vs $78.03 close before publication (Sep 21) · not market-adjusted
TEM chart →